CD274 and diffuse large B-cell lymphoma: As alluded to earlier in this review, most of these deregulated pathways have revealed capacity to ultimately impact PD-L1 levels within the DLBCL cell, highlighting a secondary immune-modulatory potential that might be further exploited by current immune-checkpoint modalities.